Repeated measures of hypocretin-1 in Danish and Italian patients with narcolepsy and in controls

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

The assay currently used worldwide to measure cerebrospinal fluid hypocretin-1 (CSF-hcrt-1) for diagnosing narcolepsy uses a competitive radioimmunoassay with polyclonal anti-hcrt-1 antibodies. This assay detects multiple hypocretin-1 immunoreactive species in the CSF that are all derived from full-length hcrt-1. We aimed to revalidate CSF-hcrt-1 cut-offs for narcolepsy type 1 (NT1) diagnosis and to evaluate temporal changes in CSF-hcrt-1 levels in patients suspected of having central hypersomnia
OriginalsprogEngelsk
TidsskriftSleep Medicine
Vol/bind101
Sider (fra-til)213-220
Antal sider8
ISSN1389-9457
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
Dr. Kornum reports other from Ceremedy ApS, outside the submitted work, and has a patent PCT/DK2020/050197 pending. Dr. Plazzi reports personal fees from UCB pharma, Jazz pharmaceuticals, IDORSIA and Bioprojet, for work other than that presented here. Dr. Mignot reports non-financial support from Idorsia Pharmaceuticals Ltd, and having received personal fees from Jazz Pharmaceutical, Alairion, ALPCO, INEXIA, Merck, Orexia, Dreem and Sunovion while the study was being carried out.We are indebted to all the patients who participated in this study, without whose contribution it would not have been possible. We thank the assistants who performed the electrophysiological examinations and the nurses who assisted with the lumbar punctures. We thank our departmental secretaries for helping with patients and study administration. We thank Mads C. J Barløse for contributing to our dataset, and Michael Ipsen, for helping with the statistical analysis. We are grateful to Philip Mason for language and copy-editing support.

Publisher Copyright:
© 2022

ID: 331639555